Drug Trial Radar · NCT07932795
Study of Multiple Ascending Doses (MAD) of M5542 in Participants With Moderate and Severe Eczema
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
56
Planned (sponsor's estimate)
Start
Dec 20, 2026
Primary completion
Aug 14, 2028
Study completion Aug 14, 2028
Sponsor
- Lead sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
- Sponsor type
- Industry
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the safety and tolerability of multiple ascending dose (MAD) of M5542 in participants with Eczema.
Conditions
- Eczema
Interventions
M5542Biological
Participants will receive loading dose of M5542 followed by maintenance doses as determined by the Safety Monitoring Committee (SMC).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs) and AEs Leading to Study Intervention DiscontinuationTime frame: From Day 1 (Baseline) up to end of Safety Follow-Up (Week 29)
- Number of Participants with Clinically Significant Changes from Baseline in Safety Laboratory AssessmentsTime frame: From Day 1 (Baseline) up to end of Safety Follow-Up (Week 29)
- Number of Participants with Clinically Significant Changes from Baseline in 12-Lead Electrocardiograms (ECGs)Time frame: From Day 1 (Baseline) up to end of Safety Follow-Up (Week 29)
- Number of Participants with Clinically Significant Changes from Baseline in Vital SignsTime frame: From Day 1 (Baseline) up to end of Safety Follow-Up (Week 29)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Darmstadt, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.